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Abstract  1 
Objectives: To assess and quantify medetomidine contamination level present in multidose vials of 2 
butorphanol in small animal general practices and determine if practice policies and procedures 3 
regarding drug handling, as determined by questionnaire, impact upon contamination level. 4 
Methods: Samples of butorphanol were withdrawn from in use vials in participating practices in June 5 
and July 2013. Samples were analysed using high-performance liquid chromatography and mass 6 
spectrometry.  7 
Results: 41 samples were obtained from 31 practices.  Contamination was detected in 29 samples 8 
from 10 mL vials.  In those contaminated samples the average level of contamination was 0.275 +/- 9 
0.393 μg.mL-1 (mean +/- SD).  The maximum level of contamination was 2.034 μg.mL-1. There was no 10 
significant correlation between volume of the vial used and the level of contamination. None of the 11 
survey factors predicted the presence or absence of measured contamination within the vials. 12 
Clinical Significance: Contamination of butorphanol multidose vials with medetomidine was 13 
common. However, the level of contamination was insufficient to cause detrimental effects in dogs 14 
when butorphanol is administered alone. The potential for sporadic higher levels of contamination 15 
must be taken into account especially when using 50mL vials when sedating critically ill cases as this 16 
could result in clinical side effects.  17 
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 20 
Introduction 21 
Butorphanol is marketed as an analgesic and sedative agent and is frequently used in veterinary 22 
practice. Although it is most commonly used in combination with medetomidine; used alone it 23 
provides mild sedation (Girard et al. 2010) without any major cardiovascular side effects (Trim 1983). 24 
This makes butorphanol a particularly useful sedative agent when dealing with patients with 25 
cardiovascular disease (Karas 1999). 26 
Butorphanol is commonly administered with medetomidine in the same syringe resulting in 27 
profound sedation. In contrast to butorphanol, medetomidine has profound effects on the 28 
cardiovascular system and can reduce cardiac output by up to 70%. These effects are still 29 
pronounced at as little as 1/20th of the widely used data sheet recommended dose of 20 μg.kg-1 in 30 
dogs and would be clinically significant in those animals with certain cardiovascular diseases 31 
(Pypendop & Verstegen 1998). 32 
Butorphanol is supplied in either a 50mL or a 10mL multidose vial in the UK. While Strachan et al. 33 
(2008) have shown that significant bacterial contamination may occur with repeated punctures of 34 
multidose vials of propofol, alfaxalone and thiopentone, no studies have addressed the potential for 35 
contamination with other drugs. We believe that the common practice of drawing up both 36 
medetomidine and butorphanol in the same syringe leads to contamination due to negative 37 
pressure within the vials. Using a hypothetical mathematical model, clinically significant 38 
contamination of vials is evident even if small volumes (5 μL of medetomidine) are aspirated 39 
repeatedly. This could produce potentially unwanted side effects in animals when using butorphanol 40 
alone or as part of a neuroleptanalgesic combination. 41 
This study aims to measure the concentration of medetomidine which is present as a contaminant in 42 
multidose vials of butorphanol in small animal general practices and to determine if individual 43 
practice policies and procedures regarding drug handling, as determined by questionnaire, impact 44 
upon the level of contamination present. 45 
 46 
Materials and Methods 47 
First opinion small animal practices were asked to participate in the study either during a visit from 48 
an ambulatory specialist cardiologist (CD) or by email sent to those practices commonly referring 49 
cases to the University Small Animal Teaching Hospital. All practices consented to their involvement 50 
in the study. 51 
Samples of butorphanol were withdrawn from in use vials in participating practices between June 52 
and July 2013 during practice visits by a cardiologist (CD), and during a one-day collection by another 53 
investigator (AB). Vials were inverted and the volume was withdrawn with a needle and syringe. The 54 
volume required for analysis was 0.1mL, which was stored in a plain 1mL sample container and 55 
refrigerated prior to analysis. The original volume of the butorphanol vial was recorded along with 56 
the volume remaining at the time of sampling. The volume remaining was measured by withdrawing 57 
all remaining vial contents into a 10mL syringe and noting the volume. 58 
Samples were analysed using high-resolution mass spectrometry and High-performance liquid 59 
chromatography using an ACE C18 AR column (150 x 4.6 mm with 5 µm particle size) interfaced with 60 
an Agilent 6460 QQQ LC-MS system. The mobile phase consisted of 0.1% v/v formic acid in 61 
water:01% v/v formic acid in acetonitrile (65:35) at a flow rate of 0.4 ml. The ESI voltage was +4.0 kV 62 
and the medetomidine was monitored in via the transition between the molecular ion at m/z 201 63 
and the fragment ion at m/z 95 using a collision energy of 15 V with argon as the collision gas. The 64 
samples were diluted extensively to prevent distortion effects in the chromatography from the much 65 
larger butorphanol peak, thus a calibration curve was prepared over the range 8.8 x 10-5 – 0.0132 66 
μg.mL-1 and had a correlation coefficient of 0.999. The precisions for repeat analysis (n=5) of the 67 
points at 8.8 x 10-5, 8.8 x 10-4 and 0.0132 μg.mL-1  were ±8.5%, ±2.5% and ±0.72% respectively and 68 
the limit of detection determined from the regression line was 2.8 x 10-5 μg.mL-1. 69 
Practice principles were asked to complete a short survey concerning sedation practices (Appendix 70 
1). This was conducted either on paper or using an internet survey tool (Surveymonkey Inc, 71 
California, USA). All statistical analysis was performed using SPSS statistics (IBM SPSS Statistics for 72 
Windows, Version 22.0. IBM, Armonk, NY). Correlations between the level of contamination and the 73 
volume of the vial used were examined using Pearson correlation. Contamination was classified as a 74 
binary outcome and tabulation of results and Pearson Chi-square was used to investigate the link 75 
between contamination and survey response.  Additionally, Mann–Whitney U-tests were used to 76 
compare the level of contamination between groups as defined by survey responses. 77 
There was deemed to be potential for contamination in the vial if the responses to the survey 78 
indicated that medetomidine was drawn into a syringe before butorphanol when drawing up drug 79 
combinations. Statistical significance was defined as a p value less than 0.05. 80 
Results 81 
41 samples were obtained from 31 participating practices with a maximum of 2 samples per 82 
practice. Samples from 10 mL vials accounted for 39 of the samples and 2 samples came from 50 mL 83 
vials. The average volume remaining in 10 mL vials when sampling occurred was 3.1 +/- 2.7 mL 84 
(mean +/- SD). Contamination was detected in 29 samples from 10 mL vials. In those contaminated 85 
samples the average level of contamination was 0.275 +/- 0.393 μg.mL-1 (mean +/- SD). The 86 
maximum level of contamination documented was 2.034 μg.mL-1 and the distribution of values is 87 
shown in figure 1. Of the two 50mL vials sampled, one was uncontaminated and contamination in 88 
one was measured at 1.483 μg.mL-1; in this vial a 7mL volume remained. There was no significant 89 
correlation between the volume of the vial used and the level of contamination (figure 2) unless the 90 
50mL vials were included in the analysis, when a statistically significant but weak correlation was 91 
evident (R = 0.51, p = 0.04).  92 
Practices were questioned as to whether dexmedetomidine was used this would have affected the 93 
chemical analysis (HPLC phase) and samples would have been treated differently, however all 94 
practices used medetomidine exclusively. In 22 practices (71%) the drugs were drawn up by a 95 
veterinary surgeon compared with 8 practices (26%) where nurses drew up the medications and 1 96 
practice (3%) where both were responsible. The use of separate syringes was only reported by 1 97 
practice. A formal SOP existed in 6 (20%) of the practices. 67% of respondents drew up 98 
medetomidine before butorphanol when drawing up a dog sedation and 64% would draw up 99 
medetomidine before butorphanol when preparing a cat premedication. Combining these there was 100 
potential for contamination of the butorphanol vial with medetomidine in 24 (78%) of practices in 101 
this study. None of the survey factors reported above were significantly associated with the 102 
presence or absence of measured contamination within the vials or the level of contamination. 103 
Discussion 104 
The results of the practice survey presented here demonstrate that medetomidine is commonly 105 
combined with butorphanol in the same syringe. In 78% of the practices surveyed, there was 106 
potential for contamination of the butorphanol multidose vials as medetomidine was drawn up 107 
before butorphanol in the same syringe. This practice undoubtedly contributes to the relatively high 108 
incidence of contamination of butorphanol multidose vials seen here. 109 
Administration of medetomidine results in a decrease in heart rate and cardiac output and an initial 110 
increase in arterial blood pressure. A number of previous studies have determined the dose of 111 
medetomidine which results in cardiovascular effects. Beths (2008) determined the effective dose 112 
(ED50) of intravenous medetomidine which affected both heart rate and systolic arterial blood 113 
pressure. The HR decreased at an ED50 of medetomidine of 0.187μg.kg-1, and the SABP increased at 114 
an ED50 of 2.05 μg.kg-1. There was minimal effect on HR and SABP at doses below 0.1 μg.kg-1. 115 
Pypendop & Verstegen (1998) evaluated the cardiovascular effects of medetomidine at different IV 116 
doses ranging from 1 to 20 μg.kg-1. Medetomidine given at a dose of 1 μg.kg-1 IV, resulted in both 117 
cardiac index and heart rate decreasing to approximately half of normal. 118 
The licensed dose for butorphanol is 0.2 to 0.3 mg.kg-1 given intravenously, intramuscularly or 119 
subcutaneously in dogs when administered alone (Butorphanol Datasheet). When butorphanol is 120 
combined with a sedative, the dose is reduced to 0.1 mg.kg-1. Butorphanol may be used alone for 121 
sedation in some patients; particularly those with significant cardiovascular disease where the side 122 
effects of sedatives such as medetomidine could cause significant morbidity. Clearly cardiac disease 123 
is a broad category comprising multiple conditions of differing aetiologies and pathogenesis, and the 124 
potential for clinically significant morbidity after medetomidine may differ depending on the 125 
condition. Lamont et al (2002) reported that the administration of medetomidine to cats with 126 
dynamic left ventricular outflow tract obstruction and ventricular hypertrophy may result in 127 
elimination of outflow tract obstruction. While α-2 agonists have been advocated as suitable 128 
sedatives in some cardiac disease patients such as cats with hypertrophic cardiomyopathy and some 129 
cases of canine aortic stenosis, we should still be cautious about their use and be aware if we are 130 
administering the drugs. An unexpected reduction in heart rate would be interpreted rather 131 
differently in the presence of α-2 agonist administration. We also do not fully understand, based on 132 
clinical evidence, the effects of α-2 agonists in cardiac disease of different aetiologies and caution is 133 
advised as inappropriate coronary vasoconstriction induced by dexmedetomidine, might cause 134 
myocardial hypoxia (Murrell & Hellebrekers 2005).   135 
Based on the average level of contamination detected in this study, a case receiving butorphanol 136 
from a contaminated vial at the licensed dose would receive only 0.006 μg.kg-1 of medetomidine. If 137 
the multidose vial was contaminated at the maximum level observed here, that dose of 138 
medetomidine would be 0.04 μg.kg-1. Although contamination is consistently present, the amount of 139 
medetomidine a patient would receive, even at the maximum contamination level detected would 140 
likely not be clinically significant and is unlikely to cause cardiovascular effects in dogs as it 141 
represents approximately one fifth of the ED50 for effects on heart rate. Nevertheless all the studies 142 
of cardiovascular effects of medetomidine have been conducted on healthy dogs with normal 143 
cardiovascular reserves and vascular tone. In dogs with cardiac compromise the effect could be 144 
more significant. 145 
However, we have demonstrated a weak correlation between the volume withdrawn from a vial and 146 
the level of contamination when 50 mL vials were considered. This result must be treated with 147 
caution due to the low sample size. This correlation does however seem plausible as one would 148 
expect contamination to increase the more times the vial is punctured. Each time the vial is 149 
contaminated during puncture, a small volume is removed; so additional punctures contaminate a 150 
lower volume. This potentially results in an exponential increase in medetomidine concentration 151 
within the vial. As such, there is a theoretical possibility that a 50 mL vial could be more 152 
contaminated by a factor of at least 5 times the maximum demonstrated here with 10 mL vials. This 153 
level of contamination would be at the ED50 for medetomidine’s effects on heat rate and caution 154 
should be exercised when using butorphanol from larger vials as a single agent for sedation in 155 
critically ill patients.  156 
A number of clinical practices which should have reduced the likelihood of vial contamination were 157 
investigated by the practice survey.  While a practice stating that they routinely drew up the drugs in 158 
separate syringes should have eliminated contamination, this was not associated with a reduction in 159 
the incidence of contamination. This finding seems counterintuitive and probably reflects the fact 160 
that the survey was filled out by one senior member of the practice, while a much greater number of 161 
staff members drew up the drugs, not always abiding by the procedures deemed appropriate by the 162 
senior staff. As only 1 practice in the survey drew up the drugs in separate syringes the sample size is 163 
too small to draw firm conclusions. There was also no evidence here that the staff member drawing 164 
up the drugs (veterinary surgeon/nurse) or the presence of a standard operating procedure for 165 
drawing up the drugs had an effect on vial contamination.  166 
We did not ascertain how long the vials sampled had been in use for in the practices and this 167 
represents a limitation. The UK summary of product characteristics (SPC) states that vials should be 168 
discarded after 28 days and if vials were used beyond this it could have affected the level of 169 
contamination present. However it is not clear exactly the effect this would have. Excessively long 170 
duration use of vials could potentially have led to degradation of contaminating medetomidine. 171 
There are no data available that describe the stability of medetomidine in butorphanol specifically. 172 
However, the most common cause of degradation of drugs is extremes of pH and since both drugs 173 
are of a similar pH (Zoetis and Orion Pharma; personal communications) and remain in the same 174 
vehicle it is unlikely there would be significant degradation. Also, there is no obvious chemical 175 
incompatibility between the two drugs based on structure.  176 
Using vials for over 28 days could also have led to more punctures being made and a higher level of 177 
contamination. The authors acknowledge the number of broaches would have been useful to 178 
document for each vial but it was not practicable during data collection and volume remaining was 179 
used as a surrogate. Irrespective of limitations surrounding the number of broaches and potential 180 
prolonged vial usage beyond SPC recommendations it is important to note that all the vials were still 181 
in use in practices. Drugs from these vials would have been administered to patients after sampling 182 
and as such the study documents the clinical level of contamination that is occurring in a sample of 183 
UK practices. Finally, we took the samples in good faith from veterinary professionals and while we 184 
did not record vial broach dates, we would expect that the SPC advice was followed in the majority 185 
of the cases yet the majority of samples were contaminated. 186 
While in this study we did not demonstrate clinically significant levels of contamination the sample 187 
size was relatively small and a risk of greater contamination on a one-off basis exists with potentially 188 
very severe consequences. Contamination of the butorphanol vial was widespread, albeit not 189 
clinically significant, and practices should consider implementing procedures which would be 190 
considered best-practice such as withdrawing drugs into separate syringes.  One should also bear in 191 
mind the potential for contamination when using other potent drugs in multidose vials. While we did 192 
not investigate any other vial types in this study, a level of contamination, which may or may not be 193 
clinically significant, would be expected where vial withdrawal techniques are similar. 194 
In conclusion, contamination of butorphanol multidose vials with medetomidine was common in 195 
small animal general practices. However the level of contamination found in the study was 196 
insufficient to cause detrimental effects in dogs when administering butorphanol as a single sedative 197 
agent. In the absence of further data, veterinary surgeons should be cautious when using 198 
butorphanol alone for sedation in critically ill cases; particularly when using the larger 50mL vials as 199 
contamination in these vials could reach a clinically significant level.  200 
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Appendix 1 - Practice Questionnaire 232 
The following questions are related to the drawing up of drugs for sedation/premedication for 233 
general anaesthesia in your practice 234 
a. Who usually draws up the drugs? 235 
☐ Veterinary Surgeon ☐ Veterinary nurse 236 
b. Are separate syringes used to draw up different drugs?  237 
☐ Yes ☐No 238 
c. If you have to draw up the following drugs in the same syringe, what order would you draw 239 
them up? Place in the box, one (1) for the first drug, two (2) for the second drug and three (3) for 240 
the third drug. (For example, cat sedation: [1] Medetomidine, [3] Butorphanol, [2] Ketamine) 241 
Dog sedation/premedication: ☐Medetomidine ☐Butorphanol 242 
Cat sedation/premedication: ☐Medetomidine ☐Butorphanol☐Ketamine 243 
d. Is there a policy or SOP in place for this protocol?  244 
☐ Yes ☐No  245 
 246 
Figure 1. Histogram showing the distribution of contamination in the 29 vials of contaminated 247 
butorphanol in the study (10 mL vials) 248 
Figure 2. Scatter plot showing the correlation between volume of the vial used and contamination 249 
(10 mL vials)  250 
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